CytomX Therapeutics, Inc. CTMX
2.70
(0.05)
(1.82%)
as of 25 Sep
- Market cap
- $599.2M
- P/E
- 0.0×
Follow CTMX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
8.00 | 0.00 | 0.00 | 0.00 |
| P/S ratio | 4.63 | 7.71 | 23.44 | 44.86 | |
| P/FCF ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/Operating CF | (33.85) | (25.28) | (32.61) | (45.44) | |
| P/B ratio | 4.90 | 5.93 | 2.60 | 2.72 | |
| Price to Tangible BV | 4.97 | 6.02 | 2.62 | 2.73 | |
| EV/Sales | 3.41 | 5.97 | 13.82 | 27.01 | |
| EV/EBITDA | 17.41 | 0.00 | 0.00 | 0.00 | |
| EV/Operating CF | (5.36) | (6.02) | (6.13) | (6.00) | |
| EV/FCF | (5.35) | (6.00) | (6.11) | (5.98) | |
| Quick Ratio | 3.54 | 2.98 | 10.21 | 9.25 | |
| Current Ratio | 3.64 | 3.09 | 10.38 | 9.36 | |
| Net Debt/EBITDA | 8.83 | 4.87 | 17.21 | 13.16 | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 0.76 | 0.56 | 0.16 | 0.07 | |
| Operating CF/Net income | 1.09 | 0.79 | 1.40 | 0.87 | |
| Capex/Depreciation | (0.25) | 0.96 | 0.00 | 0.00 | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 256.65% | 3,202.71% | 187.54% | 1,241.04% | |
| Selling, General and Administrative Expense of Revenue | 107.78% | 1,110.11% | 104.23% | 536.04% | |
| Intangible Assets out of Total Assets | 0.01 | 0.01 | 0.00 | 0.00 | |
| Share Based Compensation of Revenue | 23.21% | 223.08% | 45.88% | 181.73% | |
| Graham Net Nets | 0.19 | 0.16 | 0.38 | 0.36 | |
| Graham Number | 2.42 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 12.50% | (0.97%) | (8.75%) | (13.33%) | |
| Free Cash Flow Yield | (13.75%) | (12.90%) | (9.64%) | (10.06%) | |
| Revenue per Share | 0.04 | 0.00 | 0.06 | 0.01 | |
| Operating CF per Share | (0.09) | (0.17) | (0.14) | (0.08) | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow per Share | (0.09) | (0.17) | (0.14) | (0.08) | |
| Cash per Share | 0.87 | 0.99 | 1.96 | 1.51 | |
| Shareholders Equity per Share | 0.65 | 0.72 | 1.80 | 1.38 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 0.65 | 0.72 | 1.80 | 1.38 | |
| Free Cash Flow | (15.42) | (23.44) | (25.55) | (18.07) | |
| Working Capital | 108.19 | 97.31 | 319.07 | 333.29 | |
| Capital Expenditures | 0.13 | (0.20) | — | — | |
| Net Current Asset Value | 98.35 | 91.36 | 313.68 | 294.00 | |
| EV/EBIT | 16.66 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | (0.02) | 0.30 | 0.00 | 0.00 | |
| Net Profit Margin | (238.62%) | (4,451.28%) | (177.89%) | (1,457.40%) | |
| Price to Operating Income | 22.64 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
| Average Receivables | 2.49 | 2.56 | 1.30 | 19.68 | |
| Average Payables | 1.03 | 1.19 | 0.82 | 1.08 | |
| Average Assets | 148.62 | 136.05 | 228.93 | 278.14 | |
| Average Common Equity | 41.97 | 49.28 | 172.50 | 210.99 |
Columns are period end dates